肿瘤启动促进方案诱导的肿瘤启动剂处理的小鼠表皮和原发性小鼠皮肤肿瘤中表皮生长因子受体配体的表达改变。

Altered expression of epidermal growth factor receptor ligands in tumor promoter-treated mouse epidermis and in primary mouse skin tumors induced by an initiation-promotion protocol.

作者信息

Kiguchi K, Beltrán L, Rupp T, DiGiovanni J

机构信息

Department of Carcinogenesis, The University of Texas M. D. Anderson Cancer Center, Smithville 78957, USA.

出版信息

Mol Carcinog. 1998 Jun;22(2):73-83.

DOI:
PMID:9655251
Abstract

Multiple epidermal growth factor receptor (EGFr) ligands have been identified, including transforming growth factor alpha (TGFalpha), heparin-binding epidermal growth factor (HB-EGF), amphiregulin (AR), and betacellulin (BTC). Previous work from our laboratory demonstrated that TGFalpha mRNA and protein are upregulated in epidermis during tumor-promoter treatment of mouse skin and in skin tumors produced by initiation-promotion regimens. The purpose of the study described here was to explore the role of other EGFr ligands in multistage skin carcinogenesis. A single topical treatment of either 12-O-tetradecanoylphorbol-13-acetate (TPA) or chrysarobin or a single full-thickness wound induced the expression of HB-EGF and AR in mRNA samples isolated from whole mouse skin. However, only full-thickness wounding significantly elevated expression of the BTC transcript. The levels of HB-EGF and AR transcripts were significantly elevated in skin tumors (both papillomas and squamous cell carcinomas) induced by initiation-promotion protocols. BTC transcript levels were low and barely detectable in all skin tumors examined. The level of keratinocyte growth factor (KGF) mRNA was also examined as a possible mechanism for upregulation of EGFr ligands. Only full-thickness wounding significantly elevated KGF transcript levels in whole-skin RNA samples. Furthermore, no evidence for upregulation of KGF mRNA in skin tumors was obtained. The results are discussed in terms of the role of EGFr activation in skin carcinogenesis and the mechanisms for altered regulation of EGFr ligands.

摘要

已鉴定出多种表皮生长因子受体(EGFr)配体,包括转化生长因子α(TGFα)、肝素结合表皮生长因子(HB-EGF)、双调蛋白(AR)和β细胞素(BTC)。我们实验室先前的研究表明,在小鼠皮肤肿瘤促进剂处理期间以及启动-促进方案产生的皮肤肿瘤中,表皮中的TGFα mRNA和蛋白上调。本文所述研究的目的是探讨其他EGFr配体在皮肤多阶段致癌过程中的作用。单次局部应用12-O-十四酰佛波醇-13-乙酸酯(TPA)或柯桠素或单次全层伤口诱导从全层小鼠皮肤分离的mRNA样本中HB-EGF和AR的表达。然而,只有全层伤口显著提高了BTC转录本的表达。在启动-促进方案诱导的皮肤肿瘤(乳头状瘤和鳞状细胞癌)中,HB-EGF和AR转录本的水平显著升高。在所有检查的皮肤肿瘤中,BTC转录本水平较低且几乎检测不到。还检测了角质形成细胞生长因子(KGF)mRNA的水平,作为EGFr配体上调的一种可能机制。只有全层伤口显著提高了全层皮肤RNA样本中KGF转录本的水平。此外,未获得皮肤肿瘤中KGF mRNA上调的证据。将根据EGFr激活在皮肤致癌中的作用以及EGFr配体调节改变的机制对结果进行讨论。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索